Overview

  • Product name

    Anti-IGFBP3 antibody [EPR22152-22]
    See all IGFBP3 primary antibodies
  • Description

    Rabbit monoclonal [EPR22152-22] to IGFBP3
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, IPmore details
  • Species reactivity

    Reacts with: Mouse, Rat
  • Immunogen

    Recombinant fragment within Mouse IGFBP3 aa 1 to the C-terminus. The exact sequence is proprietary.
    Database link: P47878

  • Positive control

    • WB: Mouse IGFBP3 recombinant protein (aa22-291); Mouse lung primary cell culture supernatant; Mouse serum; Rat serum. IP: Rat serum; Mouse serum.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab220429 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 46, 29 kDa (predicted molecular weight: 32 kDa).
IP 1/30.

Target

  • Relevance

    Insulin like growth factor binding protein 3 (IGFBP3) is a member of the superfamily of insulin like growth factor (IGF) binding proteins which include six high affinity IGF binding proteins (IGFBP) and at least four low affinity binding proteins referred to as IGFBP related proteins (IGFBPrP). The IGFBP members are cysteine rich proteins with conserved cysteine residues clustered in the amino terminal and the carboxy terminal regions of the molecule. The cDNA sequence encoding the mature human IGFBP3 is fused to the signal peptide of CD33. Human IGFBP3 is the major IGF binding protein in plasma where it exists in a ternary complex with IGFI or IGFII and an acid labile subunit. IGFBPs hold a central position in IGF ligand-receptor interactions through influences on both the bioavailability and distribution of IGFs in the extracellular environment. Insulin like growth factor binding protein 3 (IGFBP3) can modulate the mitogenic and metabolic effects of the insulin like growth factors (IGFs). Insulin like growth factor binding protein 3 (IGFBP3) is expressed in multiple tissues. The highest expression level is found in the non paranchymal cells of the liver. The expression levels are higher during extrauterine life and peak during puberty. Insulin like growth factors (IGFs) and IGF binding proteins (IGFBPs) play important roles in cell growth and differentiation. IGFBP3 is one of the factors in serum that is responsible for high serum induced apoptosis in PC3 cells, a prostate cancer cell line. IGFBP3 is important in controlling glucose homeostasis with increased urinary levels in type I diabetes with persistent microalbuminuria.
  • Cellular localization

    Secreted
  • Database links

  • Alternative names

    • Acid stable subunit of the 140 K IGF complex antibody
    • Binding protein 29 antibody
    • Binding protein 53 antibody
    • BP 53 antibody
    • BP53 antibody
    • Growth hormone dependent binding protein antibody
    • IBP 3 antibody
    • IBP3 antibody
    • IGF binding protein 3 antibody
    • IGFBP 3 antibody
    • Insulin Like Growth Factor Binding Protein 3 antibody
    see all

Images

  • All lanes : Anti-IGFBP3 antibody [EPR22152-22] (ab220429) at 1/1000 dilution

    Lane 1 : Mouse lung primary cell culture supernatant at 20 µl
    Lane 2 : Mouse serum at 20 µg
    Lane 3 : Rat serum at 20 µg

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/50000 dilution

    Predicted band size: 32 kDa
    Observed band size: 29,46 kDa
    why is the actual band size different from the predicted?



    Blocking and dilution buffer: 5% NFDM/TBST.

    Exposure times.

    Lane 1: 8 seconds, Lane 2: 81 seconds, Lane 3: 3 minutes

    IGFBP3 exists as both glycosylated (46 kDa) and non-glycosylated (29 kDa) form. The molecular weight observed is consistent with what has been described in the literature (PMID 10352394; PMID: 9698597; PMID 22910030).

     

  • Anti-IGFBP3 antibody [EPR22152-22] (ab220429) at 1/1000 dilution + Mouse IGFBP3 recombinant protein (aa22-291) at 0.02 µg

    Secondary
    Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/50000 dilution

    Predicted band size: 32 kDa
    Observed band size: 29,46 kDa why is the actual band size different from the predicted?


    Exposure time: 3 seconds


    Blocking and dilution buffer: 5% NFDM/TBST.

    The recombinant fragment was expressed in a mammalian expression system.

  • IGFBP3 was immunoprecipitated from 0.35 mg of mouse serum with ab220429 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab220429 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/5000 dilution.

    Lane 1: Mouse serum 10 μg (Input).
    Lane 2: ab220429 IP in mouse serum (+).
    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab20429 in mouse serum.

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.
    Exposure time: 30 seconds.

    Non-glycosylated IGFBP-3 (29 kDa) is detected in mouse serum. The molecular weight observed is consistent with what has been described in the literature (PMID 10352394).

  • IGFBP3 was immunoprecipitated from 0.35 mg of rat serum with ab220429 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab220429 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/5000 dilution.

    Lane 1: Rat serum 10 μg (Input). 
    Lane 2: ab220429 IP in rat serum (+). 
    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab20429 in rat serum.

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.
    Exposure time: 30 seconds.

    Both glycosylated (46 kDa) and non-glycosylated (29 kDa) IGFBP-3 are detected in rat serum. The molecular weight observed is consistent with what has been described in the literature (PMID 10352394; PMID: 9698597).

References

ab220429 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab220429.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up